Rinken A, Ferré S, Terasmaa A, Owman C, Fuxe K
Institute of Chemical Physics, University of Tartu, Estonia.
Neuroreport. 1999 Feb 25;10(3):493-5. doi: 10.1097/00001756-199902250-00009.
RAT dopamine D2short receptors expressed in CHO cells were characterized by activation of [35S]GTPgammaS binding. There were no significant differences between the maximal effects seen in activation of [35S]GTPgammaS binding caused by dopaminergic agonists, but the effects of 5-HT, 8OH-DPAT and 5-methoxytryptamine amounted to 47 +/- 7%, 43 +/- 5% and 70 +/- 7% of the dopamine effect, respectively. The dopaminergic antagonist (+)butaclamol inhibited activations of both types of ligands with equal potency (pA2 = 8.9 +/- 0.1), indicating that only one type of receptor is involved. In competition with [3H]raclopride binding, dopaminergic agonists showed 53 +/- 2% of the binding sites in the GTP-dependent high-affinity state, whereas 5-HT showed only 20 +/- 3%. Taken together, the results indicate that serotonergic agonists behave as typical partial agonists for D2 receptors with potential antiparkinsonian activity.
通过[35S]GTPγS结合的激活来表征在中国仓鼠卵巢(CHO)细胞中表达的大鼠多巴胺D2短受体。多巴胺能激动剂引起的[35S]GTPγS结合激活的最大效应之间没有显著差异,但5-羟色胺(5-HT)、8-羟基二丙胺基四氢萘(8OH-DPAT)和5-甲氧基色胺的效应分别相当于多巴胺效应的47±7%、43±5%和70±7%。多巴胺能拮抗剂(+)布他拉莫以相同的效力抑制两种配体的激活(pA2 = 8.9±0.1),表明只涉及一种类型的受体。在与[3H]雷氯必利结合的竞争中,多巴胺能激动剂在GTP依赖的高亲和力状态下显示出53±2%的结合位点,而5-HT仅显示20±3%。综上所述,结果表明血清素能激动剂表现为具有潜在抗帕金森病活性的D2受体典型部分激动剂。